Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia

@article{Hanssens2007PharmacologicalTO,
  title={Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia},
  author={L. Hanssens and M. De Hert and D. Kalnick{\'a} and R. van Winkel and M. Wampers and D. van Eyck and A. Scheen and J. Peuskens},
  journal={International Clinical Psychopharmacology},
  year={2007},
  volume={22},
  pages={43-49}
}
Mortality rates in patients with schizophrenia are double compared with the general population, with cardiovascular disease causing 50% of the excess. Lowering low-density lipoprotein cholesterol is recognized as a primary target for the prevention of cardiovascular mortality. The effects of lipid-lowering treatment were evaluated in patients with schizophrenia. Forty-six patients with schizophrenia and with severe dyslipidaemia were identified. All were treated with antipsychotics. Patients… Expand
Cardiovascular diseases among patients with schizophrenia.
Statins and Inflammation: New Therapeutic Opportunities in Psychiatry
Metabolic syndrome in people with schizophrenia: a review
Dyslipidemia and Mental Illness
Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness.
Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension
Drug Emergent Metabolic syndrome in patients on Antipsychotic Medication
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 65 REFERENCES
Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
Schizophrenia and comorbid metabolic disorders.
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
The effects of antipsychotic therapy on serum lipids: a comprehensive review
The unhealthy lifestyle of people with schizophrenia.
...
1
2
3
4
5
...